RIVERAIN TECHNOLOGIES’ BONE SUPPRESSION AND COMPUTER AIDED DETECTION SOFTWARE RECEIVES CFDA APPROVAL
DAYTON, Ohio – September 26, 2013 – Riverain Technologies is pleased to announce that it has received approval from the China Food and Drug Administration (CFDA) for their ClearRead Bone Suppression (formerly SoftView) and Computer Aided Detection Software, ClearRead +Detect, (formerly OnGuard). With this approval, Riverain Technologies is now able to provide advanced lung disease detection applications to the Chinese market.
China has many factors that contribute to lung disease, such as a large population of heavy smokers, air pollution, and a high volume of the population exposed to toxins, pollutants, smog and chemicals in the air from poor working and living conditions. 1 The lung cancer incidence rate in Beijing has risen by 56 percent from 2001 to 2010, with most of those resulting in death.2
With the use of Riverain’s Bone Suppression and Computer Aided Detection software, lung disease can be identified and treated sooner. Riverain’s Bone Suppression image aids in the detection of 1 in 6 nodules that were previously missed3 and Riverain’s Computer Aided Detection software has been proven to identify as many as 1 in 2 nodules that were previously missed.4
“With the increasing incidence of lung cancer and complex addressability issues of the Chinese market, having cost effective, broadly accessible tools that make the most of existing technology is critical,” said Riverain CEO, Steve Worrell. “Riverain Technologies’ software provides radiologists with additional diagnostic information that allows them to detect and treat their patients earlier, when survival rates are highest.”
- Freedman M, Lo B, Seibel J, and Bromley E. Improved detection of lung nodules with novel software that suppresses the rib and clavicle shadows on chest radiographs. Radiology. July 2011. 260, 265-273
- Chen J and White C (2008). Use of CAD to Evaluate Lung Cancer on Chest Radiography. Journal of Thoracic Imaging. 23:93-96